CLINICAL ADVANCES IN
Chronic obstructive pulmonary disease (COPD) is a debilitating condition affecting approximately 24 million people in the United States. Because many pharmacologic treatments for COPD are administered via inhalation devices, proper use of these devices is critical to optimal treatment. This page provides education on the selection of appropriate COPD treatment options, including device selection, to stabilize disease and prevent exacerbations.
Supported by independent funding from
Sunovion Pharmaceuticals Inc.
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus
Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease
Steering Committee Chair
Associate Professor of Medicine; Director, Asthma Clinical Research Center, Baylor College of Medicine, Houston, Texas
Professor; Emeritus Division Chief, School of Medicine, University of North Carolina at Chapel Hill
Associate Professor, Department of Internal Medicine; Medical Director, Women’s Respiratory Health Program, University of Michigan, Ann Arbor, Michigan
Professor, Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine; Co-Director, COPD Program, National Jewish Health, Denver, Colorado
Professor of Medicine; Chief, Pulmonary and Critical Care Medicine Division, Weill Cornell Medicine, New York, New York
Professor, University of Minnesota, Minneapolis, Minnesota